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Abstract
Hepatitis C virus (HCV) is an important cause of chronic liver disease. Several highly diverse HCV genotypes exist with
potential key functional differences. The HCV NS5A protein was associated with response to interferon (IFN)-a based
therapy, and is a primary target of currently developed directly-acting antiviral compounds. NS5A is important for
replication and virus production, but has not been studied for most HCV genotypes. We studied the function of NS5A using
infectious NS5A genotype 1–7 cell culture systems, and through reverse genetics demonstrated a universal importance of
the amphipathic alpha-helix, domain I and II and the low-complexity sequence (LCS) I for HCV replication; the replicon-
enhancing LCSI mutation S225P attenuated all genotypes. Mutation of conserved prolines in LCSII led to minor reductions
in virus production for the JFH1(genotype 2a) NS5A recombinant, but had greater effects on other isolates; replication was
highly attenuated for ED43(4a) and QC69(7a) recombinants. Deletion of the conserved residues 414-428 in domain III
reduced virus production for most recombinants but not JFH1(2a). Reduced virus production was linked to attenuated
replication in all cases, but ED43(4a) and SA13(5a) also displayed impaired particle assembly. Compared to the original
H77C(1a) NS5A recombinant, the changes in LCSII and domain III reduced the amounts of NS5A present. For H77C(1a) and
TN(1a) NS5A recombinants, we observed a genetic linkage between NS5A and p7, since introduced changes in NS5A led to
changes in p7 and vice versa. Finally, NS5A function depended on genotype-specific residues in domain I, as changing
genotype 2a-specific residues to genotype 1a sequence and vice versa led to highly attenuated mutants. In conclusion, this
study identified NS5A genetic elements essential for all major HCV genotypes in infectious cell culture systems. Genotype-
or isolate- specific NS5A functional differences were identified, which will be important for understanding of HCV NS5A
function and therapeutic targeting.
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Introduction
Hepatitis C virus (HCV) chronically infects 130–170 million
people and leads to increased risk of severe liver disease. HCV
belongs to the Flaviviridae family and has a positive-strand RNA
genome containing one long open reading frame (ORF). The
ORF encodes a polyprotein that is co- and post-translationally
cleaved into structural proteins (Core, E1, E2), p7 and nonstruc-
tural (NS) proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B.
Significant diversity is found among HCV isolates, which in
phylogenetic analysis cluster into seven major genotypes and
numerous subtypes [1,2]. Genotypes, subtypes and isolates/strains
differ at around 30%, 20% and 2–10%, respectively, at the
nucleotide and amino acid level. A higher variability is found in
certain genome regions. Among different genotypes, the NS5A
protein sequence varies up to 50% in composition and by more
than 20 residues in length. Important differences between HCV
genotypes were identified in biology [3] and in sensitivity to
neutralizing antibodies [4–7]. The HCV genotype is an important
determinant for response to the current interferon (IFN)-a based
treatment regimens; sustained virological response is achieved for
80–90% of genotype 2 and 3 and for around 50% of genotype 1
and 4 infected patients [8]. Several HCV genes, including E2, NS3
and NS5A, were suggested to influence the response to IFN [9].
Directly-acting antiviral compounds are currently being developed
with the NS3 protease, the NS5B polymerase and NS5A as
primary targets [10]. Genotype- and isolate-specific responses to
treatment with directly-acting antivirals have been reported in
vitro [11,12] and in clinical trials [13,14].
The NS5A phosphoprotein is a component of the viral
replication complex [15] and consists of three domains separated
by low-complexity sequences (LCS) [16]. It is anchored to
PLoS Pathogens | www.plospathogens.org 1 May 2012 | Volume 8 | Issue 5 | e1002696intracellular membranes through the N-terminal amphipathic
alpha-helix [17,18]. A crystal structure was solved for domain I
[19,20], which contains a zinc-binding motif [16] and a highly
basic channel with RNA binding capacity [21]. The amphipathic
alpha-helix, domain I and II are essential for the genotype 1b
replicon system [16,22,23]. In LCSI and domain II, covering parts
of the binding site for the IFN-induced dsRNA-dependent protein
kinase R (PKR) [24], an IFN-sensitivity determining region
(ISDR) was described for genotype 1b [25], although, its existence
is controversial [26]. Several studies on genotype 2a suggest a
primary role for domain III in production of infectious particles
[27–29]. For most genotypes, however, the role of NS5A in the
viral life cycle has not been studied.
Until development of the genotype 2a JFH1 cell culture system
[30], and the more efficient J6/JFH1 system with the Core-NS2
region from another 2a isolate [31], studies on HCV NS5A relied
on the genotype 1b and 2a replicon systems, recapitulating only
parts of the viral life cycle [9]. J6/JFH1-based infectious cell
culture systems for NS5A genotypes 1–7 [12] allowed us to study
the function of the highly variable NS5A protein for all major
HCV genotypes in context of the complete viral life cycle. We
analyzed individual NS5A domains for their influence on steps of
the viral life cycle and found genotype- and isolate-specific effects
of introduced mutations and modifications.
Results
All seven major HCV genotypes depend on the NS5A
amphipathic alpha-helix, domain I, LCSI and domain II for
viral replication
To determine the importance of the individual NS5A domains
for the major HCV genotypes in context of the complete viral life-
cycle, we introduced selected mutations (Figure 1A) into J6/JFH1-
based NS5A genotype 1–7 recombinants, which we previously
demonstrated were infectious and efficient in vitro (Materials &
Methods) [12]. In previous studies, it was found that the Con-
1(genotype 1b) replicon system was inhibited by the I12E mutation
shown to disrupt the hydrophobic face of the amphipathic alpha-
helix [22], by C57G and C59G mutations interfering with zinc-ion
binding of domain I [16], and by mutating the conserved W329 in
domain II [23] (Numbering throughout is according to individual
H77 reference proteins, GenBank accession number AF009606).
The S225P mutation in LCSI was shown not to be permissible in
vivo when introduced into the Con-1(1b) full-length infectious
clone [32], even though it had an enhancing effect on the Con-
1(1b) replicon system [33,34]. These residues were all highly
conserved among HCV patient isolates (Figure 1B). To analyze
the effect of these mutations in cell culture, RNA transcripts of
more than 30 mutants of the H77C(1a), J4(1b), JFH1(2a), S52(3a),
ED43(4a), SA13(5a), HK6a(6a) and QC69(7a) NS5A recombi-
nants were transfected into Huh7.5 cells in parallel with the
positive control J6/JFH1 (for consistency denoted JFH1(2a)
according to the NS5A isolate) [31]. While around 30% of cells
were HCV positive one day after JFH1(2a) transfection, the I/
V12E, C57G/C59G, S225P and W329A genotype 1–7 mutants
were all highly attenuated, as no or very few HCV positive cells
were observed in immunostainings one and three days post-
transfection.
Since reversion was observed in vivo for the Con-1(1b) S225P
mutant coinciding with detection of high viral titers [32], we
followed the J4(1b) S225P mutant until it, after two weeks, infected
most cells. In virus recovered after passage to naı ¨ve cells, S225P
had reverted. Thus, for this mutant the findings in the infectious
cell culture system were in accordance with findings in vivo but not
with findings in the replicon system [33,34]. To determine
whether another mutant with a replicon-enhancing alteration
was also attenuated we changed the J4(1b) NS5A recombinant to
encode the D47 deletion, which replaces residues 235–282 in
NS5A LCSI/domain II by a single tyrosine (Figure 1A) [33]; this
mutant was followed for three weeks without detection of HCV
positive cells. Thus, the positive effect of NS5A replicon-enhancing
mutations apparently led to the opposite effect in the infectious cell
culture system.
We further investigated whether the phenotype observed for the
highly attenuated NS5A mutants corresponded to that of mutants
of other HCV nonstructural proteins previously shown to abrogate
HCV RNA replication. No HCV positive cells were observed one
day after transfection of JFH1(2a) mutants of the NS3 protease
active site (NS3pro
2, S139A [35]), the NS3 helicase active site
(NS3hel, D290A [35]), the NS4A transmembrane segment (G21V
[36]), the NS4B C-terminal end (W252S [37]), the NS5B
polymerase active site (GND-mutant, D318N [38]), for a JFH1(2a)
mutant with a stop codon in the NS3 N-terminus (Y6[stop]), or for
the JFH1(2a) NS5A domain I mutants C57G, C59G or C57G/
C59G included for comparison. However, infection emerged
subsequently for the NS3hel, NS4BW252S, NS5AC59G, NS5BGND
and NS3Stop mutants when following cultures for more than two
weeks. Reversion of the knockout mutations and the presence of
silent marker mutations engineered to exclude contamination were
confirmed by sequencing. We found that in a total of 13
experiments done with NS5BGND, 10 led to emerging infection.
Viruses recovered from five of these cultures were subsequently
sequenced, in all of which the attenuating mutation had reverted;
the marker mutations were maintained. Thus, the phenotype of
attenuated NS5A mutants corresponded to that of single
mutations of other non-structural genes expected to be detrimental
for viral replication. For these mutants, reversion was detected in
most cases. We speculate that this was due to transfected RNA
pools containing genomes that were reverted to wild-type as a
result of the high error-rate of T7 polymerase driven in vitro RNA
transcription.
Author Summary
Hepatitis C virus (HCV) is a major public health burden and
leads to chronic liver disease, including liver cirrhosis and
liver cancer. Understanding the biological functions of the
virus is crucial to the development of a vaccine and to
improve current therapy through development of directly-
acting antiviral compounds. The NS5A protein is a
promising antiviral target, but much remains to be
understood about its role in the viral life cycle. Great
diversity among the seven major HCV genotypes poses
challenges for broadly active inhibitors. Here we used
infectious cell culture systems for NS5A of the seven major
HCV genotypes, and demonstrated that all genotypes
depended on the NS5A amphipathic alpha-helix, domain I,
low-complexity sequence (LCS) I and domain II for viral
replication. Interestingly, effects on replication and virus
production by changes in LCSII and domain III varied
greatly among NS5A isolates. Furthermore, we found that
genotype 2 had evolved genotype-specific residues in
domain I of importance for viral function. Thus, the highly
diverse sequence of the NS5A protein reflected functional
differences between HCV genotypes and isolates. Such
differences will be important to consider in understanding
HCV biology and for future development of antiviral
compounds.
HCV NS5A Genotype-Specific Functional Analysis
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domain II on viability
The W329 in the C-terminal end of NS5A domain II was found
to be of critical importance for replication of NS5A genotype 1–7
recombinants, while it was previously reported that a JFH1 NS5A
mutant with a deletion of residues 246–308 covering a large N-
terminal region of domain II (D2222–2280 mutant) apparently
was fully viable [27]. We had similar findings for a J6/JFH1 virus
without NS5A residues 250–293 [39], and therefore wanted to
investigate whether deletion of the corresponding residues was
generally permitted for NS5A isolates. Thus we constructed
H77C(1a) and TN(1a) D250–293 mutants (Figure 1A and S1) and
transfected RNA transcripts into Huh7.5 cells. Infectivity titers
after transfection were reduced for these mutants, most signif-
icantly for H77C(1a); as previously observed, titers for the
JFH1(2a) mutant were not decreased (Figure 2A). This corre-
sponded to immunostainings with 20–30% HCV positive cells one
day post-transfection, except for the H77C(1a) D250–293 mutant,
for which only 5% were positive. All recombinants spread to the
majority of cells within 8 days. Analysis of NS5A of recovered
passaged viruses of JFH1(2a), H77C(1a) and TN(1a) D250–293
mutants confirmed the deletion. Amino acid changes D444G
(D2416G) and C447R (C2419R) were identified in H77C(1a) and
TN(1a) D250–293, respectively. No NS5A changes were observed
for the JFH1(2a) mutant.
To investigate whether viral replication, assembly or release was
affected for H77C(1a) and TN(1a) D250–293 mutants, we
transfected CD81-deficient Huh7-derived S29 cells that are not
susceptible to HCV infection [40]. HCV Core levels were used as
a measure for RNA replication [41]; validation experiments
confirmed the correlation between intracellular HCV RNA and
Core levels (Figure S2). From separate cultures, assembly and
release was evaluated by titration of intra- and extra-cellular
infectivity. While replication and virus production was not affected
for the JFH1(2a) mutant, minor decreases in replication levels and
intracellular virus production was observed for TN(1a) (Figure 2B
and C). The H77C(1a) mutant exhibited greater reductions, in
particular for intra- and extra-cellular virus production that was
reduced more than 10-fold. Thus, while the C-terminal region of
domain II was critical for replication of all HCV genotypes,
deletion of the N-terminal residues 250–293 led to a highly
attenuated phenotype for H77C(1a), an intermediate phenotype
for TN(1a) and no attenuation of JFH1(2a).
Isolate-specific dependence on conserved prolines in
NS5A LCSII for replication and virus production
The NS5A LCSII region was shown to influence HCV
replication and virus production [23,42]. The Con-1(1b) replicon
system was reported to be highly attenuated by the P343A LCSII
mutation [23]. However, changes at this genotype-specific position
(P343A for genotype 1 and 5, A343P for other genotypes, Figure
S1) did not influence infectivity titers after transfection of Huh7.5
cells for any of the NS5A genotype 1–7 recombinants (Figure 3A
and data not shown). No changes were identified in the complete
ORF of the recovered JFH1(2a) A343P mutant, and residue 343
had not reverted for mutants of other NS5A isolates. This was in
Figure 1. HCV NS5A residues and regions analyzed in reverse genetic studies. Numbering is according to the H77 reference NS5A
sequence (GenBank accession number AF009606). (A) Schematic drawing of the NS5A protein. The putative domains I–III (blue), are linked by LCSI
and II (black). The amphipathic alpha-helix (AAH) in domain I is predicted to cover residues 5–25 (green) [18]. A putative IFN-sensitivity determining
region (ISDR) covering residues 237–276 [25] and a PKR binding region covering residues 237–302 [24] (purple) extend from the LCSI into domain II.
Positions mutated in reverse genetic studies are indicated in black and deletions are indicated in red. An NS5A amino acid alignment of isolates
studied is shown in Figure S1. (B) Variation at positions mutated in reverse genetic studies among isolates in the most recent pre-made NS5A web-
alignment consisting of 673 entries from the Los Alamos HCV sequence database visualized as logo plot [63]. The information content at every
position is given in bits. Amino acids are colored by properties: polar (green), basic (blue), acidic (red) and hydrophobic (black). In addition to the
residues shown, a few serines were found at residues 346 and 354, while a few asparagines were found at residue 437. Residues observed in less than
two sequences were not included.
doi:10.1371/journal.ppat.1002696.g001
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[42].
In addition, we generated the JFH1(2a) P346A/P351A/P354A
and P346A/P351A/P353A/P354A/P355A LCSII mutants, in
which highly conserved prolines (Figure 1B and S1) in two putative
SH3 interaction domains [42–44] were mutated. Infectivity titers
after transfection of Huh7.5 cells were decreased ,10-fold
(Figure 3A), and the mutations did not revert after passage to
naı ¨ve cells. Next, the P346A/P351A/P354A mutations were
introduced into the NS5A genotype 1–7 recombinants, and tested
for viability in Huh7.5 cells. While supernatant HCV infectivity
titers were only slightly decreased for the J4(1b) mutant, reductions
by 10-fold or more were observed for H77C(1a), S52(3a),
ED43(4a), SA13(5a), HK6a(6a) and QC69(7a) mutants (data not
shown). To analyze whether attenuation was caused by reduced
replication capacities, we measured intracellular HCV Core after
transfection of S29 cells. RNA replication of ED43(4a) and
QC69(7a) P346A/P351A/P354A mutants was highly attenuated,
with intracellular HCV Core levels similar to those observed for
the NS5BGND mutant (Figure 3B). These findings were in
agreement with immunostainings, which on day 1 after transfec-
tion of Huh7.5 cells were HCV negative for the ED43(4a) and
QC69(7a) mutants. For all other LCSII mutants, replication was
decreased with up to 10-fold reductions in intracellular HCV Core
levels 48 and 72 hours post-transfection. While intra- and extra-
cellular infectivity titers from transfected S29 cells were only
slightly decreased for the J4(1b) and JFH1(2a) mutants (Figure 3C),
greater than 10-fold reductions were observed for the H77C(1a),
S52(3a), SA13(5a) and HK6a(6a) mutants. Thus the P346A/
P351A/P354A mutations had a profound impact on intracellular
virus production for some NS5A isolates but not for others. No
infectivity was observed for the ED43(4a) and QC69(7a) mutants,
as expected from RNA replication assays. Thus, various NS5A
isolates tolerated changes in LCSII to different extents. The
ED43(4a) and QC69(7a) mutants were highly attenuated in viral
replication compared to other isolates, while assembly of
intracellular infectious viral particles was affected by LCSII
mutations at an isolate-specific level.
The importance of a conserved region in NS5A domain III
for replication and virus production depends on the
NS5A isolate
In genotype 2a studies, NS5A domain III was reported to have
a primary role in virus production, e.g. deletion of JFH1 domain
III significantly attenuated virus production while replication was
less affected [23,27,28]. The high degree of sequence conservation
of residues 414-428 (Figure S1) suggested an important function of
this region; thus we generated deletion mutants for the NS5A
genotype 1–7 recombinants (Figure 1A). While the JFH1(2a)
D414-428 mutant was not attenuated, infectivity titers after
transfection of Huh7.5 cells were decreased up to 10-fold for
deletion mutants of other NS5A isolates (Figure 4A). This
correlated with previous reports on a 382–428 JFH1 deletion
mutant [27]. After spread of infection in culture and passage to
naı ¨ve cells, sequencing of the ORF from recovered viruses
confirmed the deletion for all recombinants and identified changes
for the H77C(1a), TN(1a), S52(3a), SA13(5a) and QC69(7a)
deletion mutants, primarily in the NS5A region downstream of the
deletion and in p7, NS2 and NS3 (Table 1).
To analyze whether attenuation of D414-428 mutants was
caused by reduced replication capacities, we measured intracel-
lular HCV Core after transfection of S29 cells. For most mutants,
replication was decreased less than 2-fold, but greater than 3-fold
reductions in intracellular Core were observed at multiple time
points after transfection with H77C(1a), TN(1a) and S52(3a)
mutants (Figure 4B). The effect of deletion mutants on intra- and
extra-cellular infectivity after transfection of S29 cells correspond-
ed to observations from Huh7.5 culture supernatant, with greater
than 3-fold reductions in titers for the H77C(1a), J6(2a), S52(3a),
ED43(4a) and SA13(5a) recombinants; in this assay JFH1(2a) and
QC69(7a) were not affected by the deletion (Figure 4C). For most
recombinants, reductions in replication capacities could explain
Figure 2. Infectivity titers and replication capacity of NS5A genotype 1a and 2a recombinants with N-terminal deletion in domain II.
(A) Infectivity was measured in supernatants after transfection of Huh7.5 cells with RNA transcripts from H77C(1a), TN(1a) or JFH1(2a) with and
without deletion of residues 250–293 (D250–293) (Figure S1). The lower limit of detection in the experiments shown was 10
2.3 FFU/mL (indicated by
the y-axis break). (B) As a measure for HCV RNA replication, S29 cells were transfected for 4 hours and intracellular HCV Core levels were measured
after 4, 24, 48 and 72-hours. Values were normalized for transfection efficiency using 4-hour Core amounts of the respective recombinant. The
JFH1(2a) NS5BGND mutant was included as a replication negative control. (C) Intra- and extracellular infectivity titers 48 hours after transfection of S29
cells. Intracellular titers are given per well of 4610
5 transfected S29 cells. #: no FFU were detected. Colored boxes indicate the NS5A isolate and
(genotype). Error bars indicate SEM of triplicate determinations.
doi:10.1371/journal.ppat.1002696.g002
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the less than 2-fold decrease in replication capacity for the
ED43(4a) and SA13(5a) mutants is not likely to explain the greater
than 3-fold reductions in intra- and extracellular titers observed.
This indicated an effect on virus assembly in addition to the effect
on replication for certain NS5A isolates.
Todeterminewhetherthe genotype 2-specific20 residue insertion
immediately downstream of residue 428 (Figure 1A and S1) could be
responsible for the efficient replication and virus production of the
JFH1(2a) D414-428 mutant (Figure 4), we replaced the 414-428
region of the H77C(1a) recombinant by the JFH1-specific insertion.
For this mutant, ‘‘D414-428+20aa’’, replication capacity was slightly
decreased, but unlike for the H77C(1a) D414-428 mutant, no
attenuation of intra- or extracellular infectivity was observed and no
additional mutations were identified after passage to naı ¨ve cells.
Thus, the genotype 2-specific insertion could potentially compensate
for the deletion of residues 414-428.
Serines in domain III play an important role for genotype 2a
NS5A function [28,29,45]; in particular the S437A mutation
(Figure 1) was reported to attenuate J6/JFH1 virus production
[28]. After transfection of Huh7.5 cells with RNA transcripts of
S437A mutants of NS5A genotype 1–7 we did, however, not
identify significant attenuation of virus production (Figure 5 and
data not shown). No changes were identified in the ORF of the
recovered JFH1(2a) S437A mutant and residue 437 had not
reverted for mutants of other NS5A isolates.
We further analyzed the conserved arginine/lysine motif at
residue 356–359 and the partially conserved 363–380 region that
covers the completely conserved residues 363, 372 and 376. Huh7.5
cells were transfected with JFH1(2a) mutants containing point
mutations or a deletion of the 363–380 region (Figure 1 and S1). A
minor decrease in infectivity titers was observed for the R356A/
R357A/R358A/R359A mutant, but not for L363A/L372A,
L363H/L372H or D363–380 mutants (Figure 5). We confirmed
the presence of point mutations and the 363–380 deletion in
recovered virus after passage to naı ¨ve Huh7.5 cells. Thus, no major
effect of the introduced mutations was observed, even after deletion
of a larger conserved region of NS5A domain III.
NS5A domain III was previously reported to be important for
efficient virus production of genotype 2a [27,29]. The present
findings indicate that domain III is also of importance for
replication, with isolate-specific dependence on the highly
conserved 414-428 region for replication and virus assembly.
NS5A stability is decreased by mutations in LCSII and
domain III
To further investigate the functional impact of mutations in
LCSII and domain III, we analyzed the potential effect on NS5A
stability. Due to limitations in available NS5A antibodies recogniz-
ing domain III deletion mutants of the different isolates, we focused
this analysis on H77C(1a) and the mutants P346A/P351A/P354A
in LCSII as well as D414-428 and ‘‘D414-428+20aa’’ in domain III.
Huh7.5 cells were transfected with the various recombinants, and
cultureswith.80%infectedcellswherelysedforanalysisinwestern
blots. To control for impact on replication, NS5A amounts were
normalized to amounts of Core. All analyzed mutants had relative
NS5A amounts decreased to 30–50% of that of the original
H77C(1a) (Figure 6). Thus, assuming that changes in NS5A did not
influence stability of Core, we concluded that the P346A/P351A/
P354A mutations in LCSII and the D414-428 deletion in domain
III decreased stability of H77C(1a) NS5A.
NS5A changes induced compensatory mutations in p7
and vice versa
As seen in Table 1, two recombinants with modifications in
NS5A domain III acquired the F26S (F772S) mutation in p7. We
previously reported that this mutation compensated for the
exchange of NS5A in the J6(2a) and ED43(4a) recombinants,
and in the DH6(1a) NS5A recombinant this residue changed to
leucine [12]. To further investigate a putative genetic linkage
between NS5A and p7 sequences, we introduced p7 F26S into
H77C(1a), TN(1a) and JFH1(2a) NS5A recombinants, which did
not rely on adaptation [12]. After transfection and passage to naı ¨ve
Huh7.5 cells we sequenced p7 and NS5A of viral genomes
recovered from supernatants. The H77C(1a) and TN(1a) mutants
acquired C447R (C2419R) or V446L (V2418L) in NS5A,
respectively, while the JFH1(2a) mutant did not acquire additional
mutations (Table 2). This was seen in four separate experiments
for each mutant, while four replicate experiments with the original
H77C(1a), TN(1a) and JFH1(2a) recombinants did not lead to
accumulation of any mutations (Table 2). No variation is observed
among genotype 1a and 2a isolates in the HCV database at these
two residues. To cross-check whether the observed changes in
NS5A of the genotype 1a recombinants compensated for the p7
mutation, we transfected H77C(1a) NS5AC447R and TN(1a)
NS5AV446L mutants in triplicates. After passage to naı ¨ve cells, all
H77C(1a) NS5AC447R cultures and two of three TN(1a) NS5AV446L
cultures acquired changes in p7, including F26S (Table 2). Most
cultures in addition acquired changes in NS5A. We hypothesized that
if the F26S (p7) and C447R or V446L (NS5A) mutations were
compensatory, combining these mutations should abolish the need for
further mutations. Indeed, after transfection and subsequent passage
of H77C(1a) p7F26SNS5AC447R and TN(1a) p7F26SNS5AV446L
mutants in triplicates, no additional mutations were observed
except for one additional coding change in NS5A for one TN(1a)
p7F26SNS5AV446L c u l t u r e( T a b l e2 ) .T h u s ,m o d i f i c a t i o n so fN S 5 A
from several isolates induced changes in p7, and p7 mutations induced
changes in NS5A for genotype 1a. JFH1(2a) apparently better
tolerated the change in p7 and did not rely on compensatory NS5A
mutations.
Functional importance of HCV NS5A genotype-specific
residues
In phylogenetic analysis of NS5A, genotype 2 clusters separately
from other genotypes. To investigate the functional significance of
Figure 3. Infectivity titers and replication capacity of HCV NS5A LCSII mutants. (A) Infectivity titers in supernatant after transfection of
Huh7.5 cells with original NS5A genotype recombinants or LCSII mutants. For the residue 343 mutants, J4 and JFH1 recombinants are shown as
representative examples, since no significant effect on titers was observed for any of the NS5A genotype 1–7 recombinants. For comparison, JFH1(2a)
was included in each experiment. The lower limit of detection in the experiments shown was 10
2.4 FFU/mL (indicated by the y-axis break). (B)A sa
measure for HCV RNA replication, S29 cells were transfected for 4 hours with original NS5A genotype recombinants and P346A/P351A/P354A
mutants, and intracellular HCV Core levels were measured after 4, 24, 48 and 72-hours. Values were normalized for transfection efficiency using 4-
hour Core amounts of the respective recombinant. The JFH1(2a) NS5BGND mutant was included as a replication negative control. (C) Intra- and
extracellular infectivity titers 48 hours after transfection of S29 cells with original NS5A genotype recombinants and P346A/P351A/P354A mutants.
Intracellular titers are given per well of 4610
5 transfected S29 cells. #: no FFU were detected. Colored boxes indicate the NS5A isolate and
(genotype). Error bars indicate SEM of triplicate determinations, except for in (B) where JFH1(2a) was included in duplicates.
doi:10.1371/journal.ppat.1002696.g003
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PLoS Pathogens | www.plospathogens.org 6 May 2012 | Volume 8 | Issue 5 | e1002696genotype-specific residues in the highly variable NS5A protein, we
changed positions in JFH1(2a), where genotype 2a residues were
different from all or almost all isolates of genotypes 1, 3, 4, 5 and 6
(Figure 7). Most of these positions were in NS5A domain I, and in
most cases genotype 2b isolates had residues identical to genotype
2a. Mutations were introduced into JFH1(2a) singly or combined:
E95T/Q97P, I110L, H124V, S126D, I140C, S151T/W152E,
Q157R, P165C/F168L/F169L and C436V. After transfection,
,10% of Huh7.5 cells were HCV positive for the I140C and
S151T/W152E mutants, while around 30% were positive for
Figure 4. Infectivity titers and replication capacity of HCV NS5A domain III D414-428 mutants. (A) Infectivity titers in supernatant after
transfection of Huh7.5 cells with original NS5A genotype recombinants and D414-428 mutants. The lower limit of detection in the experiments
shown was 10
2.4 FFU/mL (indicated by the y-axis break). (B) As a measure for HCV RNA replication, S29 cells were transfected for 4 hours and
intracellular HCV Core levels were measured after 4, 24, 48 and 72-hours. Values were normalized for transfection efficiency using 4-hour Core
amounts of the respective recombinant. The JFH1(2a) NS5BGND mutant was included as a replication negative control. (C) Intra- and extracellular
infectivity titers 48 hours after transfection of S29 cells. Intracellular titers are given per well of 4610
5 transfected S29 cells. Colored boxes indicate the
NS5A isolate and (genotype). Error bars indicate SEM of triplicate determinations, except for in (B) where JFH1(2a) was included in duplicates.
doi:10.1371/journal.ppat.1002696.g004
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these two mutants and for the E95T/Q97P, Q157R and P165C/
F168L/F169L mutants (Figure 8A). After immediate or delayed
spread of infection in the transfection culture, supernatants were
passaged to naı ¨ve cells and the NS5A gene of recovered mutants
was sequenced; the I140C and S151T/W152E mutants both
acquired V130I. In addition the I140C mutant acquired L188F,
and the S151T/W152E mutant acquired T122M. In two
independent experiments, the H124V mutant acquired I289T or
S300P in domain II. No mutations in NS5A were observed for the
other mutants. In functional analyses we investigated the five
mutants attenuated after transfection of Huh7.5 cells. As
demonstrated by measurement of intracellular HCV Core after
transfection of S29 cells, replication was highly attenuated for the
I140C and S151T/W152E mutants while Core accumulation was
delayed for the E95T/Q97P, Q157 and P165/F168/F169
mutants (Figure 8B). Intra- and extracellular infectivity titers after
transfection of S29 cells were reduced up to 10-fold for the E95/
Q97, Q157R, S151T/W152E and P165C/F168L/F169L mu-
tants, while reductions of 100-fold or more were observed for the
I140C mutant (Figure 8C). Thus the genotype 2 or 2a-specific
residues E95T/Q97P, Q157R and P165C/F168L/F169L seemed
to be important both for viral replication and intracellular virus
assembly.
To address whether the observed attenuation of JFH1(2a)
mutants was indeed due to genotype-specific requirements at the
analyzed positions, we introduced the reverse mutations into the
H77C(1a) NS5A recombinant. After transfection of Huh7.5
cultures, around 10% HCV positive cells were observed for the
T95E/P97Q, C140I, T151S/E152W and R157Q mutants, while
30% were positive for the original H77C(1a) NS5A recombinant;
no positive cells were observed for the C165P/L168F/L169F
mutant. This was reflected by decreased infectivity titers for all
mutants (Figure 8D). Thus, mutation of the H77(1a) NS5A
recombinant to genotype 2- or 2a-specific residues also led to
attenuation.
Since NS5A function depended on several genotype-specific
residues in domain I, we wanted to determine whether this
domain could function as a genotype-specific entity. We thus
replaced NS5A domain I for JFH(2a) by H77C sequence and for
H77C(1a) by JFH1 sequence, thereby generating two J6/JFH1
recombinants with either domain I or domain II–III from H77C.
After transfection into Huh7.5 cells, the H77C domain II–III
recombinant had slightly delayed viral spread and infectivity
titers decreased by more than 10-fold compared to JFH1(2a),
while the domain I recombinant was highly attenuated
(Figure 8E). Data from our previous study showed attenuation
even for a J6/JFH1-based recombinant with domain I from the
J6 isolate also of genotype 2a [12]. Thus, NS5A function
depended on genotype-specific residues in domain I and
genotype-specific interactions existed between NS5A domain I
and domain II–III.
Table 1. Non-synonymous mutations identified for HCV NS5A D414-428 deletion mutants.
Location of acquired mutations
Recombinant
A
Mutant, HCV gene
and residues p7 NS2 NS3 NS4B NS5A NS5B
H77C(1a) NS5A, D414-428 F26S (772) V68A (877) V389L (1415) I259T (1970) D441G (2413) V446M
(2418)
TN(1a) NS5A, D414-428 I64T (873) A156S (1182) I399T
(1425)
L363P (2335)
S52(3a) NS5A, D414-428 I70T (879) A380G (1406) S434P (2406) C447R
(2419)
K50T (2470)
SA13(5a) NS5A, D414-428 E79G (1105) H541Y
(1567)
S299F (2271) E439K
(2411)
QC69(7a) NS5A, D414-428 F26S (772)
ANumbering is according to individual H77 reference proteins (AF009606). Numbering according to the H77 reference polyprotein is given in parenthesis. All original
cell culture adaptive mutations, as indicated in Materials & Methods, and the engineered deletion were retained. Mutations in the ORF are listed for residues with at
least 50% change in the sequence reads. No changes were observed for D414-428 mutants of other NS5A isolates.
doi:10.1371/journal.ppat.1002696.t001
Figure 5. Infectivity titers in supernatant after transfection of
Huh7.5 cells with domain III mutants. For the S437A mutants, J4
and JFH1 recombinants are shown as representative examples, since no
significant effect on titers was observed for any of the NS5A genotype
1–7 recombinants. For comparison, JFH1(2a) was included in each
experiment. The lower limit of detection in the experiments shown was
10
2.4 FFU/mL (indicated by the y-axis break). Colored boxes indicate the
NS5A isolate and (genotype). Error bars indicate SEM of triplicate
determinations.
doi:10.1371/journal.ppat.1002696.g005
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Due to the clinical and biological importance, there has been
great interest in the study of HCV genotype-specific functional
differences [9]. However, most functional studies of HCV in
infectious culture systems have depended on a single HCV isolate
(JFH1). The NS5A protein was so far primarily studied in
genotype 1 and 2 replicon systems or in the JFH1 genotype 2a cell
culture system. Interestingly, replicon-enhancing mutations were
not permissible in vivo [32], emphasizing that conclusions from
the replicon systems should be drawn with caution. In this study,
we used infectious NS5A genotype 1–7 recombinants [12], and
demonstrated a universal dependence of viral replication on the
NS5A amphipathic alpha-helix, domain I, LCSI and domain II.
Thus, it was demonstrated that all HCV genotypes require these
domains for replication. Interestingly, isolate-specific effects of
mutations in LCSII and of deletions in domain II and III revealed
novel functional differences between NS5A isolates. Furthermore,
NS5A function was shown to depend on genotype-specific residues
in domain I, a finding that could influence the effect of directly
acting antiviral compounds directed against this NS5A domain.
Thus, functional isolate-specific differences are emerging for HCV
[3,42], which will be of critical importance for our understanding
of HCV biology and for development of antiviral strategies that
target NS5A and other regions with isolate variability.
We addressed the importance of the various regions of NS5A
for replication and virus production, by analyzing more than 80
mutants in culture. We showed that viral replication in context of
the complete life-cycle was critically dependent on the NS5A
amphipathic-alpha helix, domain I, LCSI and domain II for
isolates of genotypes 1a, 1b, 2a, 3a, 4a, 5a, 6a and 7a. The absence
of HCV positive cells by immunostaining early after transfection
corresponded to observations for knockout mutants of non-
structural proteins NS3, NS4A, NS4B, and NS5B, and a mutant
with an introduced stop-codon, all expected to abolish replication.
We demonstrated that reversion could occur even for such single-
residue mutants, potentially due to the high error-rate of the T7
polymerase used for RNA in vitro transcription. Thus, abrogation
Figure 6. NS5A stability of H77C(1a) mutants. Amounts of NS5A were compared to Core after spread of infection to .80% of Huh7.5 cells
transfected with H77C(1a) and P346A/P351A/P354A, D414-428 or ‘‘D414-428+20aa’’ mutants. (A) Western blots from a representative experiment of
NS5A (56/58 kDa for original), and Core (21 kDa) detected with antibodies H26 (Abcam) and C7-50 (Enzo Life Science), respectively. (B) Ratios
between NS5A/Core were calculated after subtraction of background using ImageJ and normalized to the original H77C(1a). Values from two
independent transfection experiments are shown.
doi:10.1371/journal.ppat.1002696.g006
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face of the amphipathic alpha-helix, mutation of two zinc-binding
cysteines in domain I, or due to exchange of a conserved
tryptophan in domain II confirmed and extended previous
findings in the Con-1(1b) replicon system [16,22,23]. Contrarily,
dependence on LCSI in the infectious cell culture system was
demonstrated by the highly attenuated phenotype caused by the
replicon-enhancing mutation S225P [33], which was also not
permissible in vivo [32]. Thus, at least for this mutant the
infectious NS5A cell culture systems reflected findings in vivo
better than replicon systems. Recently, S225P was shown to
enhance replication but inhibit HCV Core release of the full-
length Con-1(1b) isolate in vitro [46], which was not in agreement
with our data from infectious culture systems. In theory, inhibition
of virus production but not replication could be specific for the
Con-1(1b) isolate, however, the Con-1(1b) and J4(1b) NS5A
protein sequences deviate by less than 5%. Replication seemed to
depend also on highly conserved residues downstream in LCSI
Table 2. Non-synonymous mutations in the p7 and NS5A regions of H77C(1a), TN(1a) and JFH1(2a) p7 and NS5A mutants.
Location of acquired mutations
Recombinant
A Mutation p7 NS5A
H77C(1a) None - -
None - -
None - -
None - -
p7F26S - C447R (2419)
p7F26S - C447R (2419)
p7F26S - C447R (2419)
p7F26S - C447R (2419)
NS5AC447R S12I (758) A227V (2199)
NS5AC447R Y31C (777), S43F (789) D126N (2098)
NS5AC447R F19L (765), F26S (772) -
p7F26S, NS5AC447R --
p7F26S, NS5AC447R --
p7F26S, NS5AC447R --
TN(1a) None - -
None - -
None - -
None - -
p7F26S - V446L (2418)
p7F26S - V446L (2418)
p7F26S - V446L/M (2418)
p7F26S - V446L (2418)
NS5AV446L - D50V (2022)
NS5AV446L A28V (774) C39G (2011), D427G (2399)
NS5AV446L F26S (772) Y31C (777)
p7F26S, NS5AV446L - I280V (2252)
p7F26S, NS5AV446L --
p7F26S, NS5AV446L --
JFH1(2a) None - -
None - -
None - -
None - -
p7F26S S26F (772) -
p7F26S --
p7F26S --
p7F26S --
ANumbering is according to individual H77 reference proteins (AF009606). Numbering according to the H77 reference polyprotein is given in parenthesis. Only p7 and
NS5A were sequenced in these experiments. The engineered mutations were retained, except for one JFH1(2a) p7F26S mutant where the introduced p7 mutation
reverted. Mutations are listed for residues with at least 50% change in the sequence reads, except for italicized mutations that were minor. A dash indicates that no
mutations were identified.
doi:10.1371/journal.ppat.1002696.t002
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this study abolished replication, while residues 246–308 previously
were deleted in J6/JFH1 with no apparent effect on viability [27].
Interestingly, we observed decreased infectivity titers and muta-
tions in the C-terminus of NS5A for domain II D250–293 mutants
of genotype 1a but not 2a (Figure 2 and [39]). Thus, HCV
apparently shows an isolate-specific dependence on the highly
variable N-terminal region of NS5A domain II. The genotype 2
protein sequence deviates in this region from most other genotypes
(Figure S1), potentially reflected by differences in structure or
function and thereby also in the effect of the deletion. With the
critical dependence on selected residues or regions of the NS5A
amphipathic alpha-helix, domain I, LCSI and domain II for
replication, these regions would be obvious targets for antiviral
therapy [47].
Great differences in the effect on viral infectivity titers were
observed among the NS5A genotype 1–7 mutants when residues
346, 351 and 354 in LCSII were mutated, with J4(1b) and JFH(2a)
being least affected. Measurements of intracellular HCV Core
showed that most NS5A LCSII mutants had up to 10-fold reduced
replication capacities, while ED43(4a) and QC69(7a) mutants
were severely attenuated. Greater than 10-fold reductions in intra-
and extracellular infectivity for the H77C(1a), S52(3a), SA13(5a)
and HK6a(6a) mutants indicated an additional effect on virus
production for these isolates. Findings on the JFH1(2a) LCSII
mutant were in agreement with previous findings that a Con-1(1b)
Figure 7. Genotype 2 or 2a-specific positions in HCV NS5A. Residues with genotype 2 or 2a-specificity among isolates in the most recent pre-
made NS5A web-alignment consisting of 673 entries from the Los Alamos HCV sequence database, including 12 genotype 2a and 14 genotype 2b
sequences, are visualized as a logo plot [63]. The information content at every position is given in bits. Amino acids are colored by properties: polar
(green), basic (blue), acidic (red) and hydrophobic (black). JFH1 has isoleucine (I) at position 140. Residues observed at frequencies too low to appear
in the sequence logo (but observed in at least two sequences) are given below. Genotype 7a and other subtypes of genotype 2 than 2a and 2b were
not included, since no or only one NS5A sequences were available. Numbering is according to H77 reference NS5A sequence AF009606.
doi:10.1371/journal.ppat.1002696.g007
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while mutation of the infectious full-length JFH1 recombinant led
to lower levels of infectivity [42]. In line with this previous study,
we found that mutation of P346/P351/P354 inhibited replication
at an isolate-specific level. Interestingly, replication of the J4(1b)
mutant was only slightly decreased, while the Con-1(1b) P346A
replicon mutant was severely attenuated [42]. This might be due
to differences between the isolates or between the two in vitro
systems studied. Our QC69(7a) LCSII mutant lacked 14
nucleotides in the poly-pyrimidine tract (Materials & Methods),
however, it is unlikely that this caused the observed attenuation of
replication since previous studies demonstrated efficient replica-
tion of J6/JFH1 with much shorter poly-pyrimidine tracts [48]. In
agreement with previous findings for residue 343 mutants [42], we
could not confirm dependence on this position [23] for replication
of any of the NS5A recombinants.
Deletion of the highly conserved residues 414-428 led to isolate-
specific decrease in infectivity titers and replication (Figure 4). The
deletion had very limited effect on the JFH1(2a) mutant, while
most other NS5A isolate mutants had reduced replication
Figure 8. Characteristics of NS5A recombinants with mutations at genotype-specific positions. (A) Infectivity was measured in
supernatants after transfection of Huh7.5 cells with RNA transcripts from JFH1(2a) with genotype-specific mutations. For comparison, JFH1(2a) was
included in each experiment. The lower limit of detection in the experiments shown was 10
2.4 FFU/mL (indicated by the y-axis break). (B)A sa
measure for HCV RNA replication, S29 cells were transfected for 4, 24, 48 or 72 hours with JFH1(2a) carrying genotype-specific mutations and
intracellular HCV Core levels were measured. Values were normalized for transfection efficiency using an average of 4 hour Core amounts from 11
parallel transfections. The JFH1(2a) NS5BGND mutant was included as a replication negative control. (C) Intra- and extracellular infectivity titers
48 hours after transfection of S29 cells with JFH1(2a) carrying genotype-specific mutations. Intracellular titers are given per well of 4610
5 transfected
S29 cells. (D) Infectivity titers in supernatant after transfection of Huh7.5 cells with RNA transcripts from H77C(1a) NS5A recombinants with mutations
at genotype-specific positions. The lower limit of detection in the experiments shown was 10
2.3 FFU/mL (indicated by the y-axis break). (E) Growth
characteristics of domain I exchange recombinants. Huh7.5 cells were transfected with J6/JFH1, J6/JFH1(H77C-NS5ADI) or J6/JFH1(H77C-NS5ADII–III)
and cultures were followed by HCV infectivity titers released to the supernatant. The lower limit of detection in the experiments shown was 10
2.0 FFU/
mL (indicated by the y-axis break). Colored boxes indicate the NS5A isolate and (genotype). #: no FFU were detected. Error bars indicate SEM of
triplicate determinations, except for in (B) where data was included from four and three independent experiments with JFH1(2a) and the NS5BGND
mutant, respectively.
doi:10.1371/journal.ppat.1002696.g008
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H77C(1a), TN(1a) and S52(3a) mutants. Reductions in replication
capacities might explain the decrease in intra- and extracellular
titers observed for most mutants, however, the less than 2-fold
reduction in replication capacity for ED43(4a) and SA13(5a)
mutants compared to the greater than 3-fold reduction in
produced infectious particles indicated an effect of the 414-428
deletion on assembly of intracellular infectious particles for these
recombinants. The finding that a genotype 1a mutant with
residues 414-428 replaced by the downstream genotype 2-specific
insertion of 20 residues produced infectivity titers comparable to
the original NS5A recombinant, indicated that this insertion could
compensate for the 414-428 deletion. Others previously studied
JFH1 mutants without the 382–428 region [27] or the genotype 2
insertion sequence [49] and found only minor effects on
replication, production of infectious particles and co-localization
of NS5A and Core on lipid droplets [27]. This correlated with our
results with the JFH1(2a) 414-428 deletion mutant. However,
deletion of the 408–437 region [29], which covered the 414-428
region and the genotype 2 -specific sequence, or the almost entire
domain III (residues 356–439) [27] of genotype 2a, was highly
attenuating for viral infectivity but not for replication. Thus,
domain III residues outside the 414-428 region appear to be the
most important determinants of efficient virus production.
Experiments with H77C(1a) demonstrated that selected LCSII
and domain III mutants led to decreased amounts of NS5A
normalized to Core protein levels. Assuming that Core stability
was not affected by introduced mutations, this suggested a
decreased stability of the NS5A protein. Similar observations
were recently reported when two or four of the serines S432, S434,
S437 and S438 were changed to alanine in a JFH1 recombinant
carrying NS5A domain III from H77 [50]. Such effects could
possibly be associated with disruption of NS5A co-localization with
Core on lipid droplets [27] or disruption of interactions with
annexin A2 [51].
The J6/JFH1 S437A mutation was previously shown to
significantly decrease infectivity titers 48 hours after transfection
[28], however, another study indicated that mutation of at least
two of the S432, S434 and S437 residues was required for a
significant reduction of particle production and impaired NS5A-
Core interaction, and that viral kinetics were attenuated only early
after transfection [29]. Similar findings were reported in the JFH1
background with H77 NS5A domain III [50]. This might explain
why we observed only a less than 10-fold reduction in infectivity
titers on day 3 but not thereafter (Figure 5). Surprisingly, deletion
or point mutation of the relatively conserved 363–380 region in
domain III (Figure S1) did not significantly affect JFH1(2a) virus
production. Similarly, mutation of arginines 356–359 in a putative
nuclear localization signal [52] led to only slight reduction of
infectivity titers for JFH1(2a). Most interestingly, changing highly
conserved residues in NS5A LCSII and domain III of various
HCV isolates led to very different effects on replication and virus
production. This emphasizes the evolutionary development of
functional differences among the HCV genotypes in particular in
variable regions of the genome [3]. Investigation of the role of
these regions in vivo would be of interest for future studies.
When replacing the entire NS5A gene of J6/JFH1 with that of
other isolates[12],or conducting NS5A reverse genetic experiments
as done here, putative compensatory mutations were observed
outside of NS5A; particularly in p7, NS2 and NS3 (Table 1, [12]).
The F26S mutation in p7 provided adaptation to several NS5A
recombinants [12], and in this study F26S was acquired by NS5A
D414-428 deletion mutants. In addition, the p7 mutation also
adapted J6/JFH1 recombinants with genotype-specific NS3/4A
protease [53]. Interestingly, introduction of F26S into the geneti-
cally stable H77C(1a) and TN(1a) NS5A recombinants led to
compensatory mutations in NS5A domain III. Moreover, intro-
duction of these NS5A mutations led to mutations in p7, while
combining the p7 and NS5A mutations led to stable recombinants.
These findings indicated a genetic linkage between NS5A and p7.
NS5A interactions might also involve NS3/NS4A, where several
D414-428 mutants acquired changes, possibly in concert with p7 or
other proteins in the Core-NS2 region, since I399T in NS3
(I1425T) acquired by the TN(1a) mutant also adapted a Core-NS2
genotype 1a recombinant [54]. Additionally, a number of
potentially compensatory mutations for NS5A deletion mutants in
the third transmembrane domain of NS2 (Table 1), for the J4(1b)
NS5A recombinant [12], and for Core-NS2 recombinants [7],
indicated an interaction between NS5A and NS2. Pull-down, co-
localization and reverse genetic experiments demonstrated NS2
interactions with E1, E2, p7, NS3 and NS5A, and studies of
compensatory mutations identified the importance of such interac-
tions during production of virus particles [55–58]. Furthermore, the
p7 F26L mutation was shown to compensate for changes in Core
[59], possibly reflecting involvement of these proteins in viral
assembly. Unfortunately, useful antibodies targeting p7 are scarce
and the protein can not be directly detected in immunostainings.
Tagging of p7 was not compatible with efficient virus production
(data not shown and [56]), and was therefore not a useful approach
for studying protein interactions likely to take place during viral
assembly and release. Thus, despite elaborate efforts we failed to
establish co-immunoprecipitation or co-localization based evidence
for an interaction between p7 and NS5A in the infectious culture
system; better reagents are needed for conclusive studies on p7
interactions.
Mutation from genotype 2a to 1a or vice versa of the NS5A
genotype 2 or 2a-specific residues 95/97, 140, 151/152, 157 or
165/168/169 led to attenuation in cell culture. This was of
particular interest, since the introduced amino acids led to
attenuation irrespective of the presence of these amino acid
residues at the given position in numerous infectious HCV isolates.
This indicated that genotype 2 evolved specific sequence
requirements for function of NS5A domain I. Putative genotype-
specific compensatory mutations were identified for the JFH1(2a)
H124V mutant that changed serine at position 300 (domain II),
present in all genotype 2 and only few other isolates, and the
JFH1(2a) S151T/W152E mutant that changed threonine at
position 122, present only for genotype 2 and 1b isolates. Residues
130 and 188 that changed in the I140C culture are located in close
proximity to residue 140 in the NS5A domain I structure [19],
suggesting a functional interaction between these residues.
Compensatory mutations in domain II and the reduced viability
of domain I exchange recombinants suggested important geno-
type-specific interactions between domain I and other regions of
NS5A. Such interactions might in particular be between domain I
and II, since a recent study demonstrated that domain III alone
could be exchanged between H77 and JFH1 recombinants [50].
To our knowledge this is the first time the function of an HCV
protein was found to depend on genotype-specific residues. Since
NS5A inhibitors under current development target domain I
[14,47], this may pose challenges for future antiviral therapy.
Although this study significantly increases the number of studied
NS5A isolates, only a single isolate was analyzed for most
genotypes. Since differences were observed between isolates of
the same genotype, e.g. between domain II deletion mutants of
H77C(1a) and TN(1a), studies of more isolates will be important to
discriminate between isolate- and genotype-specific findings. Since
the original NS5A recombinants used in this study all were
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observed for NS5A mutants are likely to be attributed to the
particular NS5A isolate. However, it is possible that particular
mutations would render NS5A non-functional in the J6/JFH1
genetic background but not in a full-length background of that
particular isolate. Thus, it will eventually be of importance to
develop full-length cell culture systems for all HCV genotypes.
In conclusion, we demonstrated that all major genotypes
depended on the NS5A amphipathic alpha-helix, domain I, LCSI
and domain II for viral replication. Interestingly, dependence on
LCSII and domain III for HCV RNA replication and virus
production varied with the NS5A isolate. Additionally, functional
genotype-specific differences of NS5A domain I residues were
identified. Our study highlights the emerging evidence of
significant functional differences between diverse HCV isolates.
Observed differences in NS5A will be important to consider in
functional understanding and therapeutic targeting of this protein.
Further studies in vitro and in vivo will be important for
understanding and targeting this pleiotropic viral protein.
Materials and Methods
Construction of HCV recombinants
Reverse genetic studies were done with the J6/JFH1 recombinant
[31], and the J6/JFH1-based NS5A genotype 1–7 recombinants
H77C(1a), TN(1a), J4(1b)R867H,C1185S,J 6 ( 2 a ) F772S,S 5 2 ( 3 a ) D1975G,
ED43(4a)F772S,Y1644H,E2267G, SA13(5a)R1978G,S2416G,H K 6 a ( 6 a ) I2268N
and QC69(7a), expressing the entire NS5A protein (Numbering of
mutations according to the H77 reference polyprotein) [12]. Culture
adaptive mutations in NS5A are indicated in Figure S1. All mutations
analyzed in this study were introduced using site-directed mutagen-
esis. Marker mutations (according to the H77 reference ORF
sequence)introducedtoexclude contamination instudiesofreversion
were T3431C (NS3stop), G3830A (NS3pro), C4280T (NS3hel),
G5369A (NS4AG21V), C6224T (NS4BW252S), C6419T (NS5AC57G),
C6440T (NS5AC59G), T2719C or C8558T (NS5BGND). The
complete HCV sequence of final plasmid preparations was
confirmed, except for NS5A domain mutants that did not acquire
mutations in the ORF after passage in cell culture and did not
produce decreased infectivity titers after transfection. Sequencing
identified the following exceptions; J6/JFH1P165C/F168L/F169L carried
the additional non-coding C5485T mutation. The J4(1b) D414-428
and QC69(7a) P346A/P351A/P354A mutants lacked 2 and 14
nucleotides in the poly-pyrimidine tract, respectively.
Culturing, transfection, infection and evaluation of cell
cultures
Culturing of Huh7.5 hepatoma cells [31] was done as described
[60]. One day before transfection or infection, 4610
5 cells were
plated per well in six-well plates. In vitro transcription of RNA was
described previously [5]. For transfection, 2.5 mg RNA were
incubated with 5 mL Lipofectamine2000 (Invitrogen) in 500 mL
Opti-MEM (Invitrogen) for 20 min at room temperature. Cells
were incubated with transfection complexes for 16–24 hours in
growth medium. The individual transfection efficiencies of 20
independent experiments, as measured by HCV Core ELISA (see
below) after 4 hours, varied less than 2-fold from the positive
control. Intra- and extracellular infectivity titers after transfection
of S29 cells [40] were determined as described [61]. For infection
experiments, cells were inoculated with virus-containing superna-
tant for 16–24 hours. Supernatants collected during experiments
were sterile filtered and stored at 280uC.
Infected cultures were monitored by immunostaining using
mouse anti-HCV Core protein monoclonal antibody (B2, Anogen)
as described [5,60]. Infectivity titers were determined by adding
100 mL of triplicate sample dilutions (diluted 1:2 or more) to
6610
3 Huh7.5 cells/well plated out the day before on poly-D-
lysine-coated 96-well plates (Nunc). Cells were fixed and immu-
nostained for HCV 48 hours after infection using a previously
established protocol [60]. Primary antibody was Hepatitis C Virus
NS3 antibody (H23, Abcam). The previously used anti-NS5A
9E10 antibody [31] gave no signal for the J6(2a) NS5A
recombinant and for D414-428 mutants and suboptimal signals
for several other NS5A recombinants. The number of focus-
forming units (FFU) was determined by manual counting or on an
ImmunoSpot Series 5 UV Analyzer (CTL Europe GmbH) with
customized software as previously described [61]. HCV RNA
quantification was done using an in-house assay as described [60].
HCV Core ELISA
For measurement of intracellular HCV Core, 10
5 S29 cells [40]
per well plated the day before in 24-well plates were transfected
with HCV RNA transcripts for the indicated time period. After 4,
24, 48 and 72 hours, cells were trypsinized, centrifuged at 10006g
for 5 minutes at 4uC, washed in cold PBS and lysed in cold RIPA-
buffer supplemented with protease inhibitor cocktail set III
(Calbiochem). Cell lysates were clarified at 20,0006 g for
15 minutes at 4uC before measuring HCV Core levels using
ORTHO HCVantigenELISAtest kit (OrthoClinical Diagnostics).
Western blotting
Huh7.5 cells were trypsinized, washed in cold PBS and lyzed in
200 ml RIPA buffer (Thermo Scientific) with protease inhibitor
cocktail set III (Calbiochem) on ice for 10 min. Lysates were
treated with RQ1 DNase (Promega) to reduce viscosity, and
clarified by centrifugation at 20,0006g for 15 min at 4uC. Protein
lysates were loaded on 10% Bis-Tris gels (Invitrogen) and
subsequently transferred to 0.45 mm Hybond-P PVDF membranes
(GE Healthcare Amersham). Following overnight incubation with
specific antibodies (anti-core C7-50, Enzo Life Science) or anti-
NS5A (H26, Abcam) at 4uC, unsaturated chemiluminescense
images were acquired and protein amounts were quantified based
on band intensity using ImageJ.
Sequence determination of culture-derived HCV
RNA extraction, RT-PCR and direct sequence analysis
(Macrogen Inc) [60] as well as primers specific for the NS5A
region [12] were previously described. Sequence analysis was
performed with Sequencher (Gene Codes Corporation). HCV
sequences were retrieved from the European HCV database and
the Los Alamos HCV sequence database. Sequence logos were
done using WebLogo [62].
Supporting Information
Figure S1 NS5A alignment of the original amino acid sequence
of isolates used for NS5A genotype recombinants. Identical
residues are shaded in light blue, conservative in grey and blocks
of similar in green. Reference numbering is according to the H77
NS5A reference sequence (AF009606); corresponding numbering
of individual isolates is given at the beginning of each section. The
complete lengths of the individual isolates are: H77C and TN
(genotype 1a), 448 residues; J4 (1b), 447; JFH1 and J6 (2a), 466;
S52 (3a), 452; ED43 (4a), 445; SA13 (5a), 450; HK6a (6a), 451;
and QC69 (7a), 446. Residues with isolate specific cell culture
adaptive mutations are highlighted in red boxes (see Materials &
methods); corresponding numbering according to the polyprotein
is given in parentheses for consistency. Black boxes highlight
HCV NS5A Genotype-Specific Functional Analysis
PLoS Pathogens | www.plospathogens.org 14 May 2012 | Volume 8 | Issue 5 | e1002696residues analyzed in the present study and the NS5A isolate in
which mutations were introduced. Regions deleted in reverse
genetic studies are indicated with red horizontal lines below the
alignment of the given residues. The genotype 2 –specific insertion
from JFH1 inserted into the H77C(1a) D414-428 mutant was
ESDQVELQPPPQGGGVAPGS.
(TIF)
Figure S2 Comparison of intracellular HCV RNA and Core
levels. Huh7.5 cells were infected with three different doses of J6/
JFH1 (MOI=1, 0.1 or 0.01) and intracellular levels of HCV RNA
(A) and Core (B) were quantified after 4, 24, 48 and 72 hrs. (C)
48 hour (closed symbols) and 72 hour (open symbols) levels of
HCV Core (log10[fmol/L]) are plotted against HCV RNA
(log10[IU/mL]) to illustrate the linear relationship between the
two measures of HCV replication. The lower limit of detection in
the experiments shown was 1450 fmol/L HCV Core (indicated by
the y-axis break).
(TIFF)
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